|
|
Prepublished online as a Blood First Edition Paper on August 29, 2002; DOI 10.1182/blood-2002-06-1726.
 Previous Article | Table of Contents | Next Article 
Blood, 15 January 2003, Vol. 101, No. 2, pp. 699-702
NEOPLASIA
Brief report
Genetic analysis of de novo CD5+ diffuse large B-cell
lymphomas suggests an origin from a somatically mutated
CD5+ progenitor B cell
Tiemo Katzenberger,
Andreas Lohr,
Stephan Schwarz,
Martin Dreyling,
Julia Schoof,
Christina Nickenig,
Stephan Stilgenbauer,
Jörg Kalla,
M. Michaela Ott,
Hans Konrad Müller-Hermelink, and
German Ott
From the Institute of Pathology, University of
Würzburg, Department of Medicine III, University Hospital
Großhadern/LMU München, Würzburg, Germany;
Clinical Cooperative Group "Leukemia," GSF National Research Center
for Environment and Health, and Department of Internal Medicine III,
University of Ulm, Ulm, Germany.
CD5+ diffuse large B-cell lymphomas (DLBLs) have
recently been described as a particular subgroup of DLBLs. Classical
banding and interphase cytogenetic analyses targeting ATM,
TP53, and P16INK4a genes and the
D13S25 locus from 13 CD5+ DLBLs were compared
with 55 CD5 DLBLs. Additionally, analysis of somatic
mutations of the immunoglobulin heavy chain variable region
(IgVH) genes were performed in CD5+ DLBLs. CD5+
DLBLs were somatically mutated (7 of 8 cases) and were negative for
t(11;14)(q13;q32) and t(14;18)(q32;q21), whereas t(3;14)(q27;q32) was found in only one tumor. Trisomy 3 and gains on chromosomes 16/16p
and 18/18q were significantly overrepresented in CD5+
DLBLs. No ATM deletions were detected. The
prevalence of deletions at the D13S25 locus was
significantly higher in CD5+ DLBLs (4 of 12 [33%])
compared with CD5 DLBLs (4 of 42 [10%]), as were
p16INK4a deletions (33% versus 8%). On the
basis of these findings, CD5+ DLBLs are likely to arise
from the same progenitor cell as the mutated variant of
CD5+ lymphocytic lymphoma/B-cell chronic lymphocytic
leukemia (B-CLL).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Yamaguchi, N. Nakamura, R. Suzuki, Y. Kagami, M. Okamoto, R. Ichinohasama, T. Yoshino, J. Suzumiya, T. Murase, I. Miura, et al.
De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients
Haematologica,
August 1, 2008;
93(8):
1195 - 1202.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. S. Lossos and D. Morgensztern
Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma
J. Clin. Oncol.,
February 20, 2006;
24(6):
995 - 1007.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Tagawa, M. Suguro, S. Tsuzuki, K. Matsuo, S. Karnan, K. Ohshima, M. Okamoto, Y. Morishima, S. Nakamura, and M. Seto
Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma
Blood,
September 1, 2005;
106(5):
1770 - 1777.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
